Comprehensive Diagnosis of Chronic Rhinosinusitis in Clinical Practice

Abstract

Chronic rhinosinusitis (CRS) is a prevalent, complex inflammatory disorder of the nose and paranasal sinuses, significantly impacting quality of life and healthcare resources worldwide. This review presents a comprehensive and evidence-based overview of CRS, including current epidemiological data, mechanistic insights, clinical presentation, diagnostic strategies, management principles, emerging therapies, and guideline recommendations. Clinicians will find a synthesis of recent research and practical considerations to optimize diagnosis and individualized care of patients with CRS in clinical practice.

Introduction

Chronic rhinosinusitis represents one of the most common chronic diseases encountered in otolaryngology and general practice, characterized by persistent mucosal inflammation of the nose and paranasal sinuses lasting more than 12 weeks. The clinical ramifications of CRS extend beyond sinonasal symptoms, contributing to sleep disturbances, decreased productivity, and comorbid conditions such as asthma. The multifactorial etiology and heterogeneity of CRS pose diagnostic and therapeutic challenges, necessitating a structured, evidence-based approach for optimal patient outcomes. This review aims to provide healthcare professionals with an up-to-date and clinically relevant synthesis of the diagnosis and management of CRS, integrating recent guideline recommendations and emerging scientific evidence.

Epidemiology / Disease Burden

Chronic rhinosinusitis affects approximately 10–12% of the adult population worldwide, with regional variability attributed to environmental, genetic, and healthcare-related factors. The annual direct and indirect healthcare costs associated with CRS are substantial, estimated at billions of dollars in the United States alone. CRS is more prevalent in adults than children, with a slight predominance in females. Disease burden is heightened in individuals with comorbid respiratory conditions, particularly asthma and allergic rhinitis, and is associated with diminished physical and mental health-related quality of life. The socioeconomic impact of CRS is further magnified by its chronicity, frequent healthcare visits, and the need for long-term pharmacologic and surgical interventions.

Pathophysiology

The pathogenesis of CRS is multifactorial, involving host-environment interactions that lead to sustained sinonasal mucosal inflammation. CRS is broadly classified into two major phenotypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), each with distinct immunologic mechanisms. CRSwNP is primarily associated with type 2 (Th2-mediated) inflammation, characterized by elevated eosinophils, interleukin (IL)-4, IL-5, and IL-13. In contrast, CRSsNP exhibits a predominance of neutrophilic and mixed inflammatory patterns, with variable contributions from Th1 and Th17 pathways. Epithelial barrier dysfunction, impaired mucociliary clearance, microbial dysbiosis, and genetic susceptibility further contribute to the chronic inflammatory milieu. Recent advances in molecular endotyping have highlighted the heterogeneity of CRS, with implications for personalized diagnosis and therapy.

Risk Factors

Multiple risk factors contribute to the development and persistence of CRS. Environmental exposures, including tobacco smoke, air pollution, and occupational irritants, are well-established contributors. Genetic predisposition is increasingly recognized, with several single nucleotide polymorphisms implicated in immune regulation and epithelial function. Atopy, asthma, aspirin-exacerbated respiratory disease (AERD), and primary ciliary dyskinesia are notable comorbid conditions that increase CRS risk. Anatomical variations, such as septal deviation and concha bullosa, may predispose to sinus ostial obstruction. Recurrent viral upper respiratory tract infections and dental infections have also been implicated. Understanding individual risk factor profiles is essential for tailoring diagnostic and management strategies.

Clinical Features

CRS is defined by the presence of two or more cardinal symptoms persisting for at least 12 weeks: nasal obstruction or congestion, nasal discharge (anterior/posterior rhinorrhea), facial pain or pressure, and reduction or loss of smell. Additional features include cough, fatigue, and sleep disturbances. On examination, findings may include mucopurulent drainage, edema, or polyps within the middle meatus on nasal endoscopy. The clinical distinction between CRSwNP and CRSsNP is critical, as it informs diagnostic and therapeutic approaches. Symptom severity does not always correlate with objective findings, emphasizing the need for comprehensive assessment using validated symptom scores and endoscopic evaluation.

Diagnosis

Accurate diagnosis of CRS integrates clinical assessment with objective demonstration of sinonasal inflammation. Current guidelines endorse the use of nasal endoscopy and computed tomography (CT) imaging as diagnostic cornerstones. Nasal endoscopy allows direct visualization of mucosal inflammation, polyps, and purulent secretions, while also enabling tissue sampling for histopathology or microbiology if atypical features are present. CT imaging, optimally performed in the coronal plane, provides detailed anatomical information, identifies the extent of mucosal disease, and assists in preoperative planning. Differential diagnosis includes allergic rhinitis, viral URIs, neoplasms, and granulomatous diseases. Ancillary testing, such as allergy evaluation or immunodeficiency workup, may be warranted in selected cases, particularly in refractory or atypical presentations.

Treatment & Management

Management of CRS is tailored according to phenotype, severity, and response to prior therapies. Intranasal corticosteroids are the mainstay of medical therapy for both CRSwNP and CRSsNP, with demonstrated efficacy in reducing inflammation and symptom burden. Saline nasal irrigation is recommended as adjunctive therapy to improve mucociliary clearance and reduce crusting. For CRSwNP, short courses of systemic corticosteroids may be considered for severe symptoms. Antibiotics are reserved for acute exacerbations or in the presence of purulent discharge with evidence of bacterial infection. In refractory cases or those with significant anatomical obstruction, endoscopic sinus surgery is indicated to restore sinus ventilation and facilitate topical therapy delivery. Multidisciplinary management including allergists, pulmonologists, and immunologists is often beneficial.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in CRS management, particularly for patients with recalcitrant disease. Biologic therapies targeting type 2 inflammation, such as monoclonal antibodies against IL-5 (mepolizumab, reslizumab), IL-4/IL-13 (dupilumab), and IgE (omalizumab), have demonstrated efficacy in reducing polyp burden, improving quality of life, and decreasing the need for systemic steroids or surgery in CRSwNP. Ongoing research is focused on identifying novel biomarkers for endotyping, optimizing patient selection for biologics, and developing targeted therapies for non-type 2 CRS. Advances in minimally invasive surgical techniques and drug-eluting implantable devices further expand therapeutic options and improve long-term outcomes.

Guideline Recommendations

International and national guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), emphasize a structured approach to CRS diagnosis and management. Key recommendations include: confirming the diagnosis using symptom criteria and objective evidence of inflammation; initiating medical therapy with intranasal corticosteroids and saline irrigation; reserving systemic therapies and surgery for refractory cases; and considering biologic agents in appropriately selected patients with severe, uncontrolled CRSwNP. Shared decision-making and individualized care, guided by phenotype, comorbidities, and patient preferences, are cornerstones of effective CRS management.

Conclusion

Chronic rhinosinusitis remains a significant clinical challenge due to its prevalence, heterogeneity, and impact on patient well-being. Advances in understanding pathophysiology, phenotyping, and targeted therapy are transforming the diagnostic and therapeutic landscape. Accurate diagnosis relies on clinical acumen, objective assessment, and consideration of comorbidities and risk factors. Evidence-based, guideline-directed management, incorporating both established and novel interventions, offers the best prospects for improved outcomes and quality of life in patients with CRS. Ongoing research and multidisciplinary collaboration will continue to refine strategies for personalized care in this complex disease.